Vudalimab for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Sep 2021: Trial registered, NCT05032040
  2. 21 Jul 2022: Trial started, NCT05032040

The trials

NCT05032040: A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

State
Under way
Phase
Phase 2
People
170 planned
Started
21 Jul 2022
Primary completion
15 Oct 2025
Arms
vudalimab
Results
None posted
  1. 2 Sep 2021: Trial registered
  2. 21 Jul 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.